Caspase Inhibition in Islet Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Diabetes
Interventions
DRUG

IDN-6556

14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.

Trial Locations (1)

Unknown

University of Alberta, Edmonton

Sponsors
All Listed Sponsors
collaborator

Conatus Pharmaceuticals Inc.

INDUSTRY

lead

University of Alberta

OTHER

NCT01653899 - Caspase Inhibition in Islet Transplantation | Biotech Hunter | Biotech Hunter